Research News and Research

RSS

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.

22 Sep 2009

Health of American workers trending downwards

In the midst of the most vigorous national health care debate in 15 years, and at a time of heightened economic insecurity, new data on employers show that the health of employed American workers is trending downward in a number of important areas. The State of Health in the American Workforce, a report released today by the Families and Work Institute (FWI), finds that only 28% of employees today report that their overall health is "excellent," down from 34% just six years ago.

22 Sep 2009

Research reveals that thin people influence the way others around them eat

Thin friends who eat a lot could put your waistline at risk, according to a new study in the Journal of Consumer Research, which examines how other peoples' weight and food choices influence how much we eat.

22 Sep 2009

Bacterium responsible for outbreaks identified

University of Central Florida Microbiology Professor Keith Ireton has uncovered a previously unknown mechanism that plays an important role in the spread of a deadly food-borne bacterium.

22 Sep 2009

FDA announces grants to address unmet pediatric device needs

The U.S. Food and Drug Administration today announced the awarding of three grants to stimulate the development and availability of medical devices for children.

22 Sep 2009

New device could be the solution to menstrual pain

While most women experience minor pain during menstruation, for others, the pain can be severe enough to interfere with everyday activities and require medication. New research to be presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal initial findings of safety surrounding a new device that may more effectively treat menstrual pain.

22 Sep 2009

Older adults with vitamin D deficiency at a greater risk of heart disease and death

A new study by researchers at the University of Colorado Denver and Massachusetts General Hospital (MGH) shows vitamin D plays a vital role in reducing the risk of death associated with older age. The research, just published in the Journal of the American Geriatrics Society, evaluated the association between vitamin D levels in the blood and the death rates of those 65 and older. The study found that older adults with insufficient levels of vitamin D die from heart disease at greater rates that those with adequate levels of the vitamin.

22 Sep 2009

Dalton Pharma expands pharmaceutical manufacturing services

Dalton Pharma Services is pleased to announce the expansion of its pharmaceutical manufacturing services by adding Formulation Development to its list of integrated capabilities.

22 Sep 2009

Duke University awarded $19.5M to design a portable viral infection detection device

The Defense Advanced Research Projects Agency (DARPA), the research arm of the U.S. Department of Defense, has awarded Duke University $19.5 million for an effort led by the Duke Institute for Genome Sciences & Policy (IGSP) to design a portable, easy-to-use diagnostic device that can reveal who is infected with an upper respiratory virus before the first cough or sneeze.

22 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., announced today that it has entered into an agreement with Pfizer to acquire certain assets of Wyeth Pharmaceutical's Fort Dodge Animal Health business upon the closing of the global Pfizer-Wyeth merger, which is expected to occur early in the fourth quarter.

22 Sep 2009

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS).

21 Sep 2009

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Three new HealthPartners Research Foundation studies will examine ways to prevent and treat childhood obesity and hypertension. One study will look at interventions to prevent obesity in children ages 5-9, another will focus on obesity prevention in children ages 2-5, while another will examine hypertension in children and adolescents, including the quality and cost of care.

21 Sep 2009

Junk DNA could accelerate development of gene therapies

Scientists have identified how a protein enables sections of so-called junk DNA to be cut and pasted within genetic code - a finding which could speed development of gene therapies.

21 Sep 2009

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Enzo Biochem, Inc. (NYSE: ENZ), announced today that it had entered into a Cooperative Research and Development Agreement (CRADA) with the National Eye Institute, part of the National Institute of Health, to conduct a human clinical trial of Optiquel™, Enzo’s oral, proprietary therapeutic for chronic autoimmune uveitis.

21 Sep 2009

Malpractice reform in spotlight, earns mixed reviews

"Republican lawmakers have long touted federal tort reform as way to bring down health-care costs. Democrats are coming around to the same position in response to what they've heard from constituents. ... President Barack Obama recently raised the issue as an olive branch to Republicans, directing the Department of Health and Human Services to spend $25 million to help states and health-care systems try alternative methods of resolving malpractice allegations."

21 Sep 2009

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Sep 2009

Research News and Research

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Health of American workers trending downwards

Research reveals that thin people influence the way others around them eat

Bacterium responsible for outbreaks identified

FDA announces grants to address unmet pediatric device needs

New device could be the solution to menstrual pain

Older adults with vitamin D deficiency at a greater risk of heart disease and death

Dalton Pharma expands pharmaceutical manufacturing services

Duke University awarded $19.5M to design a portable viral infection detection device

Novel cleavage sites for enzyme caspase-3 identified

Boehringer Ingelheim to acquire certain assets of Wyeth Pharmaceutical after Pfizer-Wyeth merger

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Junk DNA could accelerate development of gene therapies

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

MDC scientist receives 1 million euros for diabetic research

Enzo Biochem and NEI join to conduct a human clinical trial of Enzo’s chronic autoimmune uveitis therapeutic

Malpractice reform in spotlight, earns mixed reviews

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News